Search Results

You are looking at 61 - 70 of 199 items for :

  • "Metastatic breast cancer" x
Clear All
Full access

NCCN Collaborates with Pfizer to Improve Provider Performance and Quality in Treatment of Metastatic Breast Cancer The NCCN Oncology Research Program (ORP) is collaborating with Pfizer Independent Grants for Learning & Change (IGLC) to

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff and Richard Zellars

to non–anthracycline-based adjuvant chemotherapy, 145 – 149 and that the dose of doxorubicin may be important. 150 Prospective evidence of the predictive use of HER2 status in early-stage 151 – 154 and metastatic breast cancer 155 – 157 is

Full access

William J. Gradishar

present with de novo metastatic breast cancer. For the latter, a dozen or so recommended treatment options exist, based largely on understanding the value of continuously leveraging the HER2 pathway. One key discovery in this area was the relative efficacy

Full access

Josh Lauring, Ben Ho Park and Antonio C. Wolff

with clinical benefit from everolimus. 57 Clinical Trials Using mTOR Inhibitors in Breast Cancer Studies of single-agent mTOR inhibitors in patients with pretreated metastatic breast cancer suggested an effect primarily on disease progression

Full access

Cell-Free DNA in a Patient With Metastatic Breast Cancer With Complete Response and Long-Term Remission Hunter Natasha 1 MD Croessmann Sarah 2 PhD Cravero Karen 3 PhD Shinn Daniel 3 BS Hurley Paula J. 2 3 PhD Park Ben Ho 2 3 MD, PhD 04 2020 18 18 4 4

Full access

Saranya Chumsri, Jodi Weidler, Siraj Ali, Sohail Balasubramanian, Gerald Wallweber, Lisa DeFazio-Eli, Ahmed Chenna, Weidong Huang, Angela DeRidder, Lindsay Goicocheal and Edith A. Perez

was not eligible for the available phase I and II trials at that time because of abnormal liver and kidney function tests. The patient was recommended for hospice. The patient presented with refractory metastatic breast cancer to our institute for a

Full access

Melinda L. Telli and Ronald M. Witteles

-stage disease settings. After its initial FDA approval in 1998 for first-line treatment of HER2-positive metastatic breast cancer in combination with paclitaxel, a series of pivotal adjuvant studies documented statistically significant improvements in both

Full access

Michaela J. Higgins, James M. Rae, David A. Flockhart, Daniel F. Hayes and Vered Stearns

: correlation with blood levels in patients with metastatic breast cancer . Biopharm Drug Dispos 1981 ; 2 : 381 – 390 . 7 Johnson MD Zou H Lee KH . Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of

Full access

Gary H. Lyman

of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer . Ann Oncol 1999 ; 10 : 553 – 560 . 49 Vogel CL Wojtukiewicz MZ Carroll RR . First and subsequent cycle use of pegfilgrastim prevents febrile

Full access

Harold J. Burstein

In November, the FDA withdrew its accelerated approval of Avastin as treatment for metastatic breast cancer. The decision was highly anticipated since the vote by the Oncology Drug Advisory Committee (ODAC) last summer voiced near unanimous